Disease · MONDO_0019457

therapy related acute myeloid leukemia and myelodysplastic syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. therapy related acute myeloid leukemia and myelodysplastic syndrome. Diseases, record MONDO_0019457. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019457

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: therapy related acute myeloid leukemia and myelodysplastic syndrome; Open Targets
Open Targets ID: MONDO_0019457; Open Targets
Other names: Secondary AGL, Secondary Acute granulocytic Leukaemia, Secondary Acute granulocytic Leukemia, Secondary Acute myeloblastic Leukaemia, Secondary Acute myeloblastic Leukemia, Secondary Acute myelocytic Leukaemia, Secondary Acute myelocytic Leukemia, Secondary Acute myelogenous Leukaemia, Secondary Acute myelogenous Leukemia, Secondary Acute myeloid Leukaemia (AML), Secondary Acute myeloid Leukemia (AML), secondary AML, secondary acute myeloid leukaemia, secondary acute myeloid leukemia, therapy-related AML and myelodysplastic syndrome; Open Targets
NCI Thesaurus: C25765; NCI Thesaurus
Orphanet: ORPHA:86846; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUSULFAN	CHEMBL820	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IDARUBICIN	CHEMBL1117	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DECITABINE	CHEMBL1201129	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
PEGFILGRASTIM	CHEMBL1201568	Protein	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DAUNORUBICIN	CHEMBL178	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2/3	https://conductscience.org/library/genes/1441	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	2	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	2	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2/3	https://conductscience.org/library/genes/1788	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
CDK1	Cyclin-dependent kinase 1	1	Cyclin-dependent kinase 1 inhibitor	Phase 1	https://conductscience.org/library/genes/983	Drugs and targets
CDK2	Cyclin-dependent kinase 2	1	Cyclin-dependent kinase 2 inhibitor	Phase 1	https://conductscience.org/library/genes/1017	Drugs and targets
CDK4	Cyclin-dependent kinase 4	1	Cyclin-dependent kinase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/1019	Drugs and targets
CDK6	Cyclin-dependent kinase 6	1	Cyclin-dependent kinase 6 inhibitor	Phase 1	https://conductscience.org/library/genes/1021	Drugs and targets
CDK7	Cyclin-dependent kinase 7	1	Cyclin-dependent kinase 7 inhibitor	Phase 1	https://conductscience.org/library/genes/1022	Drugs and targets
CDK9	Cyclin-dependent kinase 9	1	Cyclin-dependent kinase 9 inhibitor	Phase 1	https://conductscience.org/library/genes/1025	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00788892	Trial of CPX-351 in Newly Diagnosed Elderly AML Patients	Phase 2	126	2018-01-12	Acute Myeloid Leukemia	CYTARABINE, DAUNORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT03298984	Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).	Phase 1	32	2021-05-24	Acute Myeloid Leukemia	ALVOCIDIB, CYTARABINE, DAUNORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT04623216	Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.	Phase 1/2	24	2025-06-03	Acute Myeloid Leukemia	AZACITIDINE, SABATOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT05449899	G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT	Phase 2/3	232		Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning	BUSULFAN, DECITABINE	Its record names the disease	ClinicalTrials.gov
NCT00002989	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Phase 3	207		Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes	BUSULFAN, CYCLOPHOSPHAMIDE, IDARUBICIN, MELPHALAN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: serious adverse events	47 of 85	16 of 41	126	NCT00788892	Trial comparisons
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: Number of Participants With Complete Remission	41 of 84	20 of 41	125	NCT00788892	Trial comparisons
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: Overall Survival Rate at 1 Year	39 of 84	18 of 41	125	NCT00788892	Trial comparisons
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: Aplasia Rate	55 of 84	15 of 41	125	NCT00788892	Trial comparisons
Arm A: CPX-351 vs Arm B: Cytarabine + Daunorubicin: Rate of Stem Cell Transplant	13 of 84	10 of 41	125	NCT00788892	Trial comparisons
Sabatolimab 400mg Mono Adults vs Sabatolimab 800mg Mono Adults: Rate of Dose Limiting Toxicities (Safety Run-in in Adult Sabatolimab 400mg & 800mg Only)	0 of 8	1 of 10	18	NCT04623216	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32998965	DERIVED	1	PubMed
24687088	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019457

GET https://conductscience.org/api/diseases/v1/MONDO_0019457/targets?page=2

API reference For AI assistants